nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—PTGS2—bile duct cancer	0.761	1	CbGaD
Sulindac—AKR1B1—pancreas—bile duct cancer	0.00379	0.129	CbGeAlD
Sulindac—PPARD—pancreas—bile duct cancer	0.00298	0.101	CbGeAlD
Sulindac—ALB—gall bladder—bile duct cancer	0.00284	0.0965	CbGeAlD
Sulindac—MAPK3—pancreas—bile duct cancer	0.00275	0.0932	CbGeAlD
Sulindac—AKR1B1—liver—bile duct cancer	0.00241	0.0818	CbGeAlD
Sulindac—PPARD—liver—bile duct cancer	0.0019	0.0643	CbGeAlD
Sulindac—AKR1B1—lymph node—bile duct cancer	0.00185	0.0627	CbGeAlD
Sulindac—MAPK3—liver—bile duct cancer	0.00175	0.0593	CbGeAlD
Sulindac—PTGS2—gall bladder—bile duct cancer	0.00155	0.0526	CbGeAlD
Sulindac—PPARD—lymph node—bile duct cancer	0.00145	0.0493	CbGeAlD
Sulindac—MAPK3—lymph node—bile duct cancer	0.00134	0.0455	CbGeAlD
Sulindac—ALB—liver—bile duct cancer	0.000834	0.0283	CbGeAlD
Sulindac—PTGS2—pancreas—bile duct cancer	0.000714	0.0242	CbGeAlD
Sulindac—ALB—lymph node—bile duct cancer	0.000639	0.0217	CbGeAlD
Sulindac—CYP1A2—liver—bile duct cancer	0.000548	0.0186	CbGeAlD
Sulindac—CYP1A1—liver—bile duct cancer	0.000541	0.0183	CbGeAlD
Sulindac—PTGS2—liver—bile duct cancer	0.000454	0.0154	CbGeAlD
Sulindac—CYP1A1—lymph node—bile duct cancer	0.000415	0.0141	CbGeAlD
Sulindac—PTGS1—lymph node—bile duct cancer	0.000364	0.0124	CbGeAlD
Sulindac—PTGS2—lymph node—bile duct cancer	0.000348	0.0118	CbGeAlD
Sulindac—MAPK3—Spinal Cord Injury—IL6—bile duct cancer	0.000134	0.000637	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—EGFR—bile duct cancer	0.000134	0.000637	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.000134	0.000637	CbGpPWpGaD
Sulindac—MAPK3—PDGFR-beta signaling pathway—HRAS—bile duct cancer	0.000133	0.000636	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—EGFR—bile duct cancer	0.000131	0.000625	CbGpPWpGaD
Sulindac—MAPK3—Toll Like Receptor 4 (TLR4) Cascade—IL6—bile duct cancer	0.00013	0.000621	CbGpPWpGaD
Sulindac—ALB—Metabolism—FAR2—bile duct cancer	0.000129	0.000616	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—KRAS—bile duct cancer	0.000128	0.000611	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—KRAS—bile duct cancer	0.000128	0.000611	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—MMP9—bile duct cancer	0.000128	0.00061	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—MMP2—bile duct cancer	0.000128	0.000609	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—KRAS—bile duct cancer	0.000128	0.000608	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—KRAS—bile duct cancer	0.000127	0.000605	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—bile duct cancer	0.000127	0.000605	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—HGF—bile duct cancer	0.000127	0.000604	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—IL6—bile duct cancer	0.000127	0.000604	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—KRAS—bile duct cancer	0.000126	0.000602	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—IL6—bile duct cancer	0.000126	0.0006	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—EGFR—bile duct cancer	0.000126	0.0006	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—EGFR—bile duct cancer	0.000126	0.0006	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—EGFR—bile duct cancer	0.000126	0.0006	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—EGFR—bile duct cancer	0.000125	0.000594	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bile duct cancer	0.000124	0.000593	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bile duct cancer	0.000124	0.000593	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—KRAS—bile duct cancer	0.000124	0.00059	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—ERBB2—bile duct cancer	0.000124	0.000589	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—EGFR—bile duct cancer	0.000124	0.000589	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—EGFR—bile duct cancer	0.000123	0.000586	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—NRAS—bile duct cancer	0.000122	0.000583	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.000122	0.000581	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—HRAS—bile duct cancer	0.000121	0.000577	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.000121	0.000575	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—NRAS—bile duct cancer	0.000119	0.000568	CbGpPWpGaD
Sulindac—MAPK3—BDNF signaling pathway—HRAS—bile duct cancer	0.000119	0.000568	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—KRAS—bile duct cancer	0.000119	0.000566	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—KRAS—bile duct cancer	0.000119	0.000566	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—KRAS—bile duct cancer	0.000119	0.000566	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.000118	0.000564	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—bile duct cancer	0.000118	0.000563	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—KRAS—bile duct cancer	0.000118	0.000561	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—bile duct cancer	0.000118	0.00056	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—IL6—bile duct cancer	0.000117	0.000559	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—KRAS—bile duct cancer	0.000117	0.000556	CbGpPWpGaD
Sulindac—ALB—Platelet degranulation—TGFB1—bile duct cancer	0.000117	0.000555	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—KRAS—bile duct cancer	0.000116	0.000554	CbGpPWpGaD
Sulindac—MAPK3—Toll-Like Receptors Cascades—IL6—bile duct cancer	0.000116	0.000553	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—IL6—bile duct cancer	0.000116	0.000553	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.000116	0.000553	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000114	0.000545	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—HRAS—bile duct cancer	0.000114	0.000544	CbGpPWpGaD
Sulindac—PPARD—Metabolism—GNAS—bile duct cancer	0.000113	0.00054	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—ERBB2—bile duct cancer	0.000112	0.000533	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TP53—bile duct cancer	0.000112	0.000533	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.000112	0.000533	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.000111	0.000531	CbGpPWpGaD
Sulindac—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—bile duct cancer	0.000111	0.000529	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.000111	0.000529	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TP53—bile duct cancer	0.00011	0.000525	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RNF43—bile duct cancer	0.00011	0.000523	CbGpPWpGaD
Sulindac—MAPK3—Insulin Signaling—HRAS—bile duct cancer	0.00011	0.000522	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MET—bile duct cancer	0.000109	0.000521	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—IL6—bile duct cancer	0.000109	0.00052	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—HRAS—bile duct cancer	0.000109	0.00052	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—HRAS—bile duct cancer	0.000109	0.000519	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—EGFR—bile duct cancer	0.000109	0.000517	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—HRAS—bile duct cancer	0.000108	0.000517	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—HRAS—bile duct cancer	0.000108	0.000514	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bile duct cancer	0.000108	0.000513	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—TGFB1—bile duct cancer	0.000107	0.000512	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—HRAS—bile duct cancer	0.000107	0.000512	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TGFB1—bile duct cancer	0.000106	0.000503	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.000105	0.000502	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—IL6—bile duct cancer	0.000104	0.000497	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—NOS2—bile duct cancer	0.000104	0.000496	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—IL6—bile duct cancer	0.000104	0.000495	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—EGFR—bile duct cancer	0.000104	0.000493	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—IL6—bile duct cancer	0.000103	0.000492	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—IL6—bile duct cancer	0.000103	0.00049	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—KRAS—bile duct cancer	0.000103	0.000489	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—IL6—bile duct cancer	0.000102	0.000488	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—bile duct cancer	0.000102	0.000485	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	0.000102	0.000484	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—TP53—bile duct cancer	0.000102	0.000484	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—HRAS—bile duct cancer	0.000101	0.000481	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.000101	0.000481	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—HRAS—bile duct cancer	0.000101	0.000481	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—IL6—bile duct cancer	0.000101	0.000479	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—HRAS—bile duct cancer	0.0001	0.000477	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—bile duct cancer	9.99e-05	0.000476	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	9.94e-05	0.000474	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—HRAS—bile duct cancer	9.93e-05	0.000473	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—HRAS—bile duct cancer	9.88e-05	0.000471	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—IDH2—bile duct cancer	9.83e-05	0.000468	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—IL6—bile duct cancer	9.67e-05	0.000461	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—IL6—bile duct cancer	9.67e-05	0.000461	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	9.67e-05	0.000461	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—MMP9—bile duct cancer	9.6e-05	0.000457	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—IL6—bile duct cancer	9.59e-05	0.000457	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—NRAS—bile duct cancer	9.57e-05	0.000456	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—IL6—bile duct cancer	9.5e-05	0.000453	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—IL6—bile duct cancer	9.46e-05	0.000451	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—NRAS—bile duct cancer	9.41e-05	0.000448	CbGpPWpGaD
Sulindac—PTGS2—Disease—RNF43—bile duct cancer	9.32e-05	0.000444	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—IL6—bile duct cancer	9.3e-05	0.000443	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—ERBB2—bile duct cancer	9.26e-05	0.000441	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MMP2—bile duct cancer	9.12e-05	0.000434	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—FAR2—bile duct cancer	9.04e-05	0.000431	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	8.95e-05	0.000426	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—HRAS—bile duct cancer	8.72e-05	0.000415	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TP53—bile duct cancer	8.69e-05	0.000414	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	8.65e-05	0.000412	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—EGFR—bile duct cancer	8.57e-05	0.000408	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	8.57e-05	0.000408	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	8.53e-05	0.000406	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—NRAS—bile duct cancer	8.52e-05	0.000406	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—IDH1—bile duct cancer	8.45e-05	0.000403	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—IL6—bile duct cancer	8.35e-05	0.000398	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	8.28e-05	0.000394	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—KRAS—bile duct cancer	8.24e-05	0.000392	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—GNAS—bile duct cancer	8.19e-05	0.00039	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—IL6—bile duct cancer	8.14e-05	0.000388	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—KRAS—bile duct cancer	8.1e-05	0.000386	CbGpPWpGaD
Sulindac—PTGS2—Disease—IDH1—bile duct cancer	8.01e-05	0.000382	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—ERBB2—bile duct cancer	7.99e-05	0.000381	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IL6—bile duct cancer	7.96e-05	0.000379	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MMP9—bile duct cancer	7.94e-05	0.000378	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—IDH2—bile duct cancer	7.8e-05	0.000372	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—EGFR—bile duct cancer	7.76e-05	0.00037	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—TP53—bile duct cancer	7.67e-05	0.000366	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	7.65e-05	0.000364	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—KRAS—bile duct cancer	7.33e-05	0.000349	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—SMAD4—bile duct cancer	7.3e-05	0.000348	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	7.18e-05	0.000342	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFBR2—bile duct cancer	7.16e-05	0.000341	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HGF—bile duct cancer	7.13e-05	0.000339	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—ERBB2—bile duct cancer	7.05e-05	0.000336	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—NRAS—bile duct cancer	7.04e-05	0.000335	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	7.04e-05	0.000335	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—IL6—bile duct cancer	7.02e-05	0.000335	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HRAS—bile duct cancer	7e-05	0.000334	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—IDH2—bile duct cancer	6.93e-05	0.00033	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—HRAS—bile duct cancer	6.88e-05	0.000328	CbGpPWpGaD
Sulindac—ALB—Hemostasis—GNAS—bile duct cancer	6.86e-05	0.000327	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MMP9—bile duct cancer	6.85e-05	0.000326	CbGpPWpGaD
Sulindac—MAPK3—Disease—SMAD4—bile duct cancer	6.78e-05	0.000323	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—IDH1—bile duct cancer	6.71e-05	0.00032	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL6—bile duct cancer	6.7e-05	0.000319	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	6.65e-05	0.000317	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—IL6—bile duct cancer	6.59e-05	0.000314	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TGFB1—bile duct cancer	6.54e-05	0.000312	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HGF—bile duct cancer	6.54e-05	0.000312	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—EGFR—bile duct cancer	6.42e-05	0.000306	CbGpPWpGaD
Sulindac—ALB—Metabolism—IDH2—bile duct cancer	6.31e-05	0.000301	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—HRAS—bile duct cancer	6.23e-05	0.000297	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTGS2—bile duct cancer	6.08e-05	0.00029	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—NRAS—bile duct cancer	6.08e-05	0.000289	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—KRAS—bile duct cancer	6.06e-05	0.000289	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—IL6—bile duct cancer	5.96e-05	0.000284	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—NRAS—bile duct cancer	5.96e-05	0.000284	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—IDH1—bile duct cancer	5.96e-05	0.000284	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—GNAS—bile duct cancer	5.94e-05	0.000283	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	5.91e-05	0.000282	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TGFB1—bile duct cancer	5.65e-05	0.000269	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—SLC5A5—bile duct cancer	5.58e-05	0.000266	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TGFB1—bile duct cancer	5.54e-05	0.000264	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—EGFR—bile duct cancer	5.54e-05	0.000264	CbGpPWpGaD
Sulindac—ALB—Metabolism—IDH1—bile duct cancer	5.43e-05	0.000259	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—bile duct cancer	5.39e-05	0.000257	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—NRAS—bile duct cancer	5.37e-05	0.000256	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—KRAS—bile duct cancer	5.23e-05	0.000249	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	5.23e-05	0.000249	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—TGFB1—bile duct cancer	5.17e-05	0.000246	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HRAS—bile duct cancer	5.15e-05	0.000245	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—KRAS—bile duct cancer	5.13e-05	0.000244	CbGpPWpGaD
Sulindac—MAPK3—Disease—NOS2—bile duct cancer	5.04e-05	0.00024	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TGFBR2—bile duct cancer	5.01e-05	0.000239	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NOS2—bile duct cancer	5.01e-05	0.000239	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL6—bile duct cancer	4.93e-05	0.000235	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—EGFR—bile duct cancer	4.89e-05	0.000233	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GNAS—bile duct cancer	4.84e-05	0.00023	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SMAD4—bile duct cancer	4.75e-05	0.000226	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KRAS—bile duct cancer	4.62e-05	0.00022	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—bile duct cancer	4.56e-05	0.000217	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—HRAS—bile duct cancer	4.45e-05	0.000212	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SLC5A5—bile duct cancer	4.43e-05	0.000211	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—IDH2—bile duct cancer	4.42e-05	0.00021	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—HRAS—bile duct cancer	4.36e-05	0.000208	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GNAS—bile duct cancer	4.33e-05	0.000206	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—bile duct cancer	4.3e-05	0.000205	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFBR2—bile duct cancer	4.26e-05	0.000203	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—IL6—bile duct cancer	4.26e-05	0.000203	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ERBB2—bile duct cancer	4.11e-05	0.000196	CbGpPWpGaD
Sulindac—PTGS2—Disease—SMAD4—bile duct cancer	4.03e-05	0.000192	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SLC5A5—bile duct cancer	3.93e-05	0.000187	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HRAS—bile duct cancer	3.93e-05	0.000187	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—IDH1—bile duct cancer	3.8e-05	0.000181	CbGpPWpGaD
Sulindac—MAPK3—Disease—ERBB2—bile duct cancer	3.79e-05	0.000181	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IL6—bile duct cancer	3.76e-05	0.000179	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTGS2—bile duct cancer	3.71e-05	0.000177	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	3.68e-05	0.000175	CbGpPWpGaD
Sulindac—ALB—Metabolism—SLC5A5—bile duct cancer	3.58e-05	0.000171	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GNAS—bile duct cancer	3.44e-05	0.000164	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—NRAS—bile duct cancer	3.42e-05	0.000163	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	3.36e-05	0.00016	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NRAS—bile duct cancer	3.13e-05	0.000149	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—EGFR—bile duct cancer	3.12e-05	0.000148	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GNAS—bile duct cancer	3.05e-05	0.000145	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOS2—bile duct cancer	3e-05	0.000143	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—bile duct cancer	2.94e-05	0.00014	CbGpPWpGaD
Sulindac—MAPK3—Disease—NRAS—bile duct cancer	2.89e-05	0.000137	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NRAS—bile duct cancer	2.87e-05	0.000137	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EGFR—bile duct cancer	2.85e-05	0.000136	CbGpPWpGaD
Sulindac—ALB—Metabolism—GNAS—bile duct cancer	2.78e-05	0.000133	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—bile duct cancer	2.69e-05	0.000128	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFB1—bile duct cancer	2.68e-05	0.000128	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TGFB1—bile duct cancer	2.67e-05	0.000127	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ERBB2—bile duct cancer	2.66e-05	0.000127	CbGpPWpGaD
Sulindac—MAPK3—Disease—EGFR—bile duct cancer	2.63e-05	0.000125	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC5A5—bile duct cancer	2.51e-05	0.000119	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRAS—bile duct cancer	2.5e-05	0.000119	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—bile duct cancer	2.48e-05	0.000118	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—bile duct cancer	2.47e-05	0.000118	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—bile duct cancer	2.4e-05	0.000114	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	2.35e-05	0.000112	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—bile duct cancer	2.33e-05	0.000111	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HRAS—bile duct cancer	2.29e-05	0.000109	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP9—bile duct cancer	2.28e-05	0.000109	CbGpPWpGaD
Sulindac—PTGS2—Disease—ERBB2—bile duct cancer	2.26e-05	0.000107	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—bile duct cancer	2.19e-05	0.000105	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—bile duct cancer	2.19e-05	0.000104	CbGpPWpGaD
Sulindac—MAPK3—Disease—HRAS—bile duct cancer	2.11e-05	0.000101	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HRAS—bile duct cancer	2.1e-05	0.0001	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NRAS—bile duct cancer	2.02e-05	9.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—bile duct cancer	2.02e-05	9.63e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GNAS—bile duct cancer	1.95e-05	9.27e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TGFB1—bile duct cancer	1.88e-05	8.95e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EGFR—bile duct cancer	1.84e-05	8.77e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—bile duct cancer	1.74e-05	8.29e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NRAS—bile duct cancer	1.72e-05	8.18e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—bile duct cancer	1.64e-05	7.81e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFB1—bile duct cancer	1.59e-05	7.6e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—EGFR—bile duct cancer	1.56e-05	7.45e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—bile duct cancer	1.55e-05	7.36e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—bile duct cancer	1.49e-05	7.12e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRAS—bile duct cancer	1.48e-05	7.04e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—bile duct cancer	1.48e-05	7.04e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—bile duct cancer	1.42e-05	6.74e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HRAS—bile duct cancer	1.26e-05	5.98e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—bile duct cancer	1.2e-05	5.73e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—bile duct cancer	1.05e-05	4.98e-05	CbGpPWpGaD
